Vectura updates on clinical progress
Chippenham, UK-based Vectura Group has published an interim management statement for the period April 1 to June 30.
This highlights: - good progress made towards start of registration studies for the asthma/chronic obstructive pulmonary disease product, VR315; - NVA 237 data from two Phase II COPD clinical trials have been accepted for presentation at the October 2008 European Respiratory Society Conference in Berlin, Germany; - first patient visit for a Phase II study on VR496 for cystic fibrosis/COPD confirmed for August 2008; - initiation of Phase IIb "at-home" study for VR040 for Parkinson's disease on schedule for fourth-quarter 2008; - positive data announced in April 2008 from an early proof-of-concept study of VR147 for the symptomatic treatment of migraine; and - other development programs, including the device accord with Boehringer Ingelheim, proceeding to plan.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze